Australia opts to label drugs developed through stem cell researchBMJ 2003; 327 doi: https://doi.org/10.1136/bmj.327.7417.700-e (Published 25 September 2003) Cite this as: BMJ 2003;327:700
- Bob Burton
The Australian government will require that drug manufacturers disclose whether material from human embryos or embryonic stem cells was used in the manufacture or testing of drugs registered after 1 July 2004.
The change is the result of lobbying by Senator Brian Harradine, a staunch Catholic who persuaded the Minister for Health, Kay Patterson, to require that information on use of embryonic material be included in literature for doctors and in product information sheets accompanying medicines.
In the parliamentary debate late last year on legislation authorising research using human embryos and stem cells, Senator Patterson argued …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial